Context Therapeutics Inc. (CNTX)
Automate Your Wheel Strategy on CNTX
With Tiblio's Option Bot, you can configure your own wheel strategy including CNTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CNTX
- Rev/Share 0.0
- Book/Share 0.9558
- PB 0.6377
- Debt/Equity 0.0021
- CurrentRatio 48.8017
- ROIC -0.3469
- MktCap 54674710.0
- FreeCF/Share -0.0062
- PFCF -93.083
- PE -2.0994
- Debt/Assets 0.0021
- DivYield 0
- ROE -0.2978
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CNTX | William Blair | -- | Outperform | -- | -- | April 21, 2025 |
| Initiation | CNTX | JMP Securities | -- | Mkt Outperform | -- | $4 | Jan. 8, 2025 |
News
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and testicular cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, …
Read More
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company's clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. “There is a high unmet need for …
Read More
Bet on These 5 Top-Ranked Stocks With Rising P/E
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
Read More
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 46,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.
Read More
About Context Therapeutics Inc. (CNTX)
- IPO Date 2021-10-20
- Website https://www.contexttherapeutics.com
- Industry Biotechnology
- CEO Mr. Martin A. Lehr
- Employees 12